In vivo challenging of polymyxins and levofloxacin eye drop against multidrug-resistant Pseudomonas aeruginosa keratitis

Journal of Infection and Chemotherapy

Volumn 20, Issue 6, 2014, Pages 343-349

  Tajima, Kazuki ^a   Miyake, Taku ^a   Koike, Naohito ^a   Hattori, Takaaki ^a   Kumakura, Shigeto ^a   Yamaguchi, Tetsuo ^a   Matsumoto, Tetsuya ^a   Fujita, Koji ^a   Kuroda, Masahiko ^a   Ito, Norihiko ^a,b,c   Goto, Hiroshi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

Colistin; Keratitis; MDRP; Polymyxin B; Pseudomonas aeruginosa; Rabbit model

Indexed keywords

COLISTIN; COLISTIN METHANESULFATE; EYE DROPS; LEVOFLOXACIN; LVFX; POLYMYXIN; POLYMYXIN B; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL KERATITIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA LESION; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; IN VIVO STUDY; KERATITIS; MALE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT PSEUDOMONAS AERUGINOSA KERATITIS; NEUTROPHIL; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RABBIT MODEL; SLIT LAMP; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOLOGY; PSEUDOMONAS INFECTIONS; RABBIT;

ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; KERATITIS; LEVOFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS;

EID: 84903714237     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2013.10.015     Document Type: Article

References (37)

1. Cheng KH, Leung SL, Hoekman HW, Beekhuis WH, Mulder PG, Geerards AJ, et al. Incidence of contact-lens-associated microbial keratitis and its related morbidity. Lancet 1999;354(9174): 181-5.
2. Yildiz EH, Airiani S, Hammersmith KM, Rapuano CJ, Laibson PR, Virdi AS, et al. Trends in contact lens-related corneal ulcers at a tertiary referral center. Cornea 2012;31(10): 1097-102.
3. Cavanagh HD, Robertson DM, Petroll WM, Jester JV. Castroviejo Lecture 2009: 40 years in search of the perfect contact lens. Cornea 2010;29(10): 1075-85.
4. Kouda S, Fujiue Y, Watanabe Y, Ohara M, Kayama S, Kato F, et al. Sporadic isolations of a multi-drug resistant Pseudomonas aeruginosa clone during a 14-month epidemic in a general hospital in Hiroshima. Infection 2011;39(3): 247-53.
5. Lee SK, Park DC, Kim MG, Boo SH, Choi YJ, Byun JY, et al. Rate of isolation and trends of antimicrobial resistance of multidrug resistant pseudomonas aeruginosa from otorrhea in chronic suppurative otitis media. Clin Exp Otorhinolaryngol 2012;5(1): 17-22.
6. Naesens R, Vlieghe E, Verbrugghe W, Jorens P, Ieven M. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 2011;11:317.
7. Bukholm G, Tannaes T, Kjelsberg AB, Smith-Erichsen N. An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit. Infect Control Hosp Epidemiol 2002;23(8): 441-6.
8. Douglas MW, Mulholland K, Denyer V, Gottlieb T. Multi-drug resistant Pseudomonas aeruginosa outbreak in a burns unitean infection control study. Burns 2001;27(2): 131-5.
9. Prokosch V, Gatzioufas Z, Thanos S, Stupp T. Microbiological findings and predisposing risk factors in corneal ulcers. Graefes Arch Clin Exp Ophthalmol 2012;250(3): 369-74.
10. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40(9): 1333-41.
11. Cho YS, Yim H, Yang HT, Hur J, Chun W, Kim JH, et al. Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea. Infection 2012;40(1): 27-33.
12. Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011;1(1):30.
13. Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2009;63(3): 534-42.
14. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6(9): 589-601.
15. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34(5): 634-40.
16. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005;25(1): 11-25.
17. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard- Ninth Edition; M07eA9. Wayne: NCCLS; 2012.
18. Seki M, Machida N, Yamagishi Y, Yoshida H, Tomono K. Nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa caused by damaged transesophageal echocardiogram probe used in cardiovascular surgical operations. J Infect Chemother 2013;19(4): 677-81.
19. Marumo K, Komukai D, Hirose M, Nakamura H, Tanaka H, Ugajin K, et al. Evaluation in vitro of the efficacy of colistin methanesulfonate against biofilmforming multidrug-resistant Pseudomonas aeruginosa (MDRP). J Infect Chemother 2013;19(2): 348-51.
20. Kawaharajo K, Homma JY. Pathogenesis of the mouse keratitis produced with Pseudomonas aeruginosa. Jpn J Exp Med 1975;45(6): 515-24.
21. Ito A, Hirai K, Inoue M, Koga H, Suzue S, Irikura T, et al. In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother 1980;17(2): 103-8.
22. Lomholt JA, Poulsen K, Kilian M. Epidemic population structure of Pseudomonas aeruginosa: evidence for a clone that is pathogenic to the eye and that has a distinct combination of virulence factors. Infect Immun 2001;69(10): 6284-95.
23. Zhu H, Conibear TC, Bandara R, Aliwarga Y, Stapleton F, Willcox MD. Type III secretion system-associated toxins, proteases, serotypes, and antibiotic resistance of Pseudomonas aeruginosa isolates associated with keratitis. Curr Eye Res 2006;31(4): 297-306.
24. Burns FR, Paterson CA, Gray RD, Wells JT. Inhibition of Pseudomonas aeruginosa elastase and Pseudomonas keratitis using a thiol-based peptide. Antimicrob Agents Chemother 1990;34(11): 2065-9.
25. Frucht-Pery J, Golan G, Hemo I, Zauberman H, Shapiro M. Efficacy of topical gentamicin treatment after 193-nm photorefractive keratectomy in an experimental Pseudomonas keratitis model. Graefes Arch Clin Exp Ophthalmol 1995;233(8): 532-4.
26. Stangogiannis-Druya E, Stangogiannis-Druya C, Naranjo-Tackman R, Vanzzini V, Villar-Kuri J. Bacterial corneal ulcer treated with intrastromal antibiotic. Experimental model in vivo. Arch Soc Esp Oftalmol 2009;84(3): 123-32.
27. Callegan MC, Hobden JA, Hill JM, Insler MS, O'Callaghan RJ. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci 1992;33(11): 3017-23.
28. Johnson MK, Hobden JA, Hagenah M, O'Callaghan RJ, Hill JM, Chen S. The role of pneumolysin in ocular infections with Streptococcus pneumoniae. Curr Eye Res 1990;9(11): 1107-14.
29. Tajima K, Sinjyo A, Ito T, Noda Y, Goto H, Ito N. Methicillin-resistant Staphylococcus aureus keratitis in a dog. Vet Ophthalmol 2013;16(3): 240-3.
30. Karthikeyan RS, Priya JL, Leal Jr SM, Toska J, Rietsch A, Prajna V, et al. Host response and bacterial virulence factor expression in Pseudomonas aeruginosa and Streptococcus pneumoniae corneal ulcers. PLoS One 2013;8(6): e64867.
31. Fleiszig SM, Wiener-Kronish JP, Miyazaki H, Vallas V, Mostov KE, Kanada D, et al. Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. Infect Immun 1997;65(2): 579-86.
32. Furtado GH, d'Azevedo PA, Santos AF, Gales AC, Pignatari AC, Medeiros EA. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2007;30(4): 315-9.
33. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007;60(6): 1206-15.
34. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003;47(8): 2659-62.
35. Chung JL, Lim EH, Song SW, Kim BY, Lee JH, Mah FS, et al. Comparative intraocular penetration of 4 fluoroquinolones after topical instillation. Cornea 2013;32(7): 1046-51.
36. Pryor JG, Apt L, Leopold IH. Intraocular penetration of colistin. Arch Ophthalmol 1962;67: 612-5.
37. Mizukawa T, Azuma I, Yukioka Y. Topical use of Colimycin-S in ophthalmology. Nihon Ganka Kiyo 1964;15: 205-13.